The DOI matches its Crossref record.
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection
Abstract
Clofazimine nanosuspensions were produced by high pressure homogenization and the formulation was optimized for lyophilization. Characterization of the product by photon correlation spectroscopy, laser diffraction and Coulter counter analysis showed that the clofazimine nanosuspensions were suitable for iv injection with a particle size permitting passive targeting to the reticuloendothelial system. Following iv administration to mice of either the nanocrystalline or a control liposomal formulation at a dose of 20 mg clofazimine/kg bodyweight, drug concentrations in livers, spleens and lungs reached comparably high concentrations, well in excess of the MIC for most Mycobacterium avium strains. When C57BL/6 mice were experimentally infected with M. avium strain TMC 724, nanocrystalline clofazimine was as effective as liposomal clofazimine in reducing bacterial loads in the liver, spleen and lungs of infected mice. Nanocrystalline suspensions of poorly soluble drugs such as riminophenazines are easy to prepare and to lyophilize for extended storage and represent a promising new drug formulation for intravenous therapy of mycobacterial infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Drug delivery systems: An updated review
Tiwari, G., Tiwari, R., Bannerjee, S., Bhati, L., Pandey, S., Pandey, P., & Sriwastawa, B. (2012) · International Journal of Pharmaceutical Investigation · doi:10.4103/2230-973x.96920 · Cited by 1,671
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Nanosuspensions in drug delivery
Rabinow, B. E. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1494 · Cited by 1,524
Nanosuspensions as particulate drug formulations in therapy
Müller, R. H., Jacobs, C., & Kayser, O. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00118-6 · Cited by 1,370
Nanosizing — Oral formulation development and biopharmaceutical evaluation
Kesisoglou, F., Panmai, S., & Wu, Y. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.003 · Cited by 1,055
Nanosuspensions: a promising drug delivery strategy
Patravale, V. B., Date, A. A., & Kulkarni, R. M. (2004) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357023691 · Cited by 904
The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis
Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200504-613pp · Cited by 745
Shegokar, R., & Müller, R. H. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.07.044 · Cited by 740
Van Eerdenbrugh, B., Van den Mooter, G., & Augustijns, P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.07.023 · Cited by 717
Drug delivery strategies for poorly water-soluble drugs
Fahr, A., & Liu, X. (2007) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.4.4.403 · Cited by 568
The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs
KIPP, J. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.07.019 · Cited by 529
Nanocrystals for enhancement of oral bioavailability of poorly water-soluble drugs
Junyaprasert, V. B., & Morakul, B. (2015) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2014.08.005 · Cited by 443
Drug nanocrystals in the commercial pharmaceutical development process
Möschwitzer, J. P. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.09.034 · Cited by 432
Gao, L., Zhang, D., & Chen, M. (2008) · Journal of Nanoparticle Research · doi:10.1007/s11051-008-9357-4 · Cited by 420
Emerging role of nanosuspensions in drug delivery systems
Jacob, S., Nair, A. B., & Shah, J. (2020) · Biomaterials Research · doi:10.1186/s40824-020-0184-8 · Cited by 415
Clofazimine: current status and future prospects
Cholo, M. C., Steel, H. C., Fourie, P. B., Germishuizen, W. A., & Anderson, R. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr444 · Cited by 351
Drug nanocrystals: in vivo performances.
Gao, L., Liu, G., Ma, J., Wang, X., Zhou, L., & Li, X. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.013 · Cited by 347
Improvement of drug safety by the use of lipid-based nanocarriers
Lim, S. B., Banerjee, A., & Önyüksel, H. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.002 · Cited by 324
New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery
Sosnik, A., Carcaboso, Á. M., Glisoni, R. J., Moretton, M. A., & Chiappetta, D. A. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.11.023 · Cited by 264
Metadata
- Authors
- Peters, K.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-01-01
- Volume
- 45
- Issue
- 1
- Pages
- 77-83
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2152352703
- Cited by
- 228
- References
- 0
- FWCI
- 0.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.